Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roman Ivankiv

Podiatrist, Foot Surgery St Augustine, FL Doctor of Podiatric Medicine

NPI 1528517331 CMS profile 5564893

1740 Tree Blvd Ste 112, St Augustine, FL 32084

Open in the dashboard

General payments

$5,599

93 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roman Ivankiv of St Augustine, FL is reported in the CMS Open Payments database as having received $5,599 across 93 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Podiatrist, Foot Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $513 8
2024 General $589 6
2023 General $1,293 21
2022 General $749 21
2021 General $1,768 23
2020 General $242 8
2019 General $445 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roman Ivankiv
  • Podiatrist, Foot Surgery median
  • Middle half of Podiatrist, Foot Surgery
  • National median

In program year 2025, general payments to Roman Ivankiv were reported at $513. Among 732 Podiatrist, Foot Surgery profiles paid that year, the median was $180 and the middle half received between $70 and $569.

Show as a table
Year Roman Ivankiv Podiatrist, Foot Surgery median Middle half National median
2019 $445 $167 $67–$484 $163
2020 $242 $114 $40–$323 $114
2021 $1,768 $171 $57–$502 $132
2022 $749 $196 $66–$556 $149
2023 $1,293 $187 $78–$466 $160
2024 $589 $190 $78–$557 $164
2025 $513 $180 $70–$569 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $1,715 21 payments
  2. Smith+Nephew, Inc. $1,012 14 payments
  3. Organogenesis Inc. $627 16 payments
  4. Arthrex, Inc. $485 7 payments
  5. Horizon Therapeutics plc $397 8 payments
  6. Cardiovascular Systems Inc. $172 2 payments
  7. Kerecis Limited $161 2 payments
  8. Paragon 28, Inc. $148 1 payment
  9. Bard Peripheral Vascular, Inc. $134 1 payment
  10. Penumbra, Inc. $121 1 payment
  11. Other $627 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,566 79 payments
  2. Travel and Lodging $1,876 12 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $157 2 payments
Products named General payments · program years 2019–2025
  1. GRAFIX $899 5 payments
  2. STRAVIX PL $899 5 payments
  3. OASIS $789 4 payments
  4. PROPHECY $769 8 payments
  5. PRIME SERIES $546 5 payments
  6. KRYSTEXXA $397 8 payments
  7. Puraply $384 13 payments
  8. PROSTEP $349 6 payments
  9. ORTHOLOC 2 LAPIFUSE $176 2 payments
  10. Kerecis Omega3 SurgiClose $161 2 payments
  11. Other $3,999 88 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

382

Median for Podiatry: 160

Drug cost

$11,969

Median for Podiatry: $2,368

Branded share of claims

23%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 20 $9,083
Diclofenac Sodium Generic 24 $636
Prednisone Generic 50 $332
Terbinafine Hcl Generic 40 $306
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 35 $236
Gabapentin Generic 40 $221
Ciprofloxacin Hcl Generic 24 $220
Ketoconazole Generic 16 $185
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 22 $180
Mupirocin Generic 23 $178

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$141,233

Medicare's payments for the services billed

Medicare patients

354

Average age 75

Services billed

1,998

205 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Diabetes 47%
Ischemic heart disease 47%
Chronic kidney disease 36%
Heart failure 29%
Depression 27%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

93 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record